A new generation of Genetically Modified (GM) vaccines: How to overcome the hurdles from bench to practice?

Flanders Vaccine’s Symposium: 

 

A new generation of Genetically Modified (GM) vaccines: How to overcome the hurdles from bench to practice?

March 19, 2019 

FOD-WASO – Ernest Blerotstraat 1, 1070 Brussels
(located on the opposite of Pullman Hotel or exit ‘Hortaplein’ of the railway station Brussels South/Midi)

REGISTRATION


To overcome the limitations of traditional vaccines, the development and use of novel types of vaccines, especially those based on GM technology, are being considered more frequently.

Although GM vaccines are endowed with unique and beneficial qualities, major regulatory -, safety – and other aspects need clarification.

  • What are the Belgian regulatory guidelines for the development of these novel types of vaccines? Is there a difference with other national regulatory frameworks in European countries?
  • What are the challenges encountered in the pre-clinical and clinical field?
  • How can we guarantee the safety and effectiveness of GM vaccines?
  • Is there an environmental risk associated with the use of GM vaccines?

Join this symposium and learn more about these current and interesting topics. A panel of experts will be happy to answer your questions and fuel the discussion.

Preliminary Program (subject to change)


12:30-13:00: Registration and Welcome Coffee

13:00-13:10: Introduction

13:10-13:40: What is a GM vaccine and which are the Belgian regulatory guidelines to follow?
By Sciensano and the Federal Agency of Medicines and Health Products

13:40-14:00: European Regulatory aspect of GM Vaccines
by Prof. Dr. Pieter Neels, IABS

14:00-14:15: Experiences from the  pre-clinical field: yellow fever vaccine-PLLAV technology
By KU Leuven

14:15-14:30: Experiences from the veterinary clinical field (to be confirmed)
by Virovet


14:30-15:00: COFFEE BREAK


15:00-15:20: Experiences from the clinical field
by Johan Van Hoof, Janssen Pharmaceutica

15:20-15:40: Experiences from the clinical field in Belgium
by Bruno Speder, SGS

15:40-16:20: Panel Discussion

16:20-16:30: Closing of the day

16:30-17:30: Networking reception


This symposium is organised in collaboration with the Federal Agency of Medicines and Health Products (FAMHP).   


For REGISTRATION, click <<here>> (registration is open until March 5, 2019)


 

Loading...